Access Statistics for Mary K. Olson

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Pharmaceutical Expenditure and Regulatory Policy in the NHS 0 0 0 0 1 2 4 336
Total Working Papers 0 0 0 0 1 2 4 336


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Agency Rulemaking, Political Influences, Regulation, and Industry Compliance 0 0 0 0 1 1 8 369
Are novel drugs more risky for patients than less novel drugs? 0 0 0 29 0 1 9 129
Eliminating the U.S. drug lag: Implications for drug safety 0 0 0 13 0 0 11 120
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity 0 0 2 4 1 1 16 37
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity 0 0 0 7 1 3 11 69
Firm Characteristics and the Speed of FDA Approval 0 0 1 42 1 1 8 150
New clinical information and physician prescribing: How do pediatric labeling changes affect prescribing to children? 0 0 0 3 0 1 9 38
Pharmaceutical Policy Change and the Safety of New Drugs 0 0 1 9 0 1 8 78
Political Influence and Regulatory Policy: The 1984 Drug Legislation 0 0 0 0 0 0 7 183
Reassessing the impact of health IT: Hidden costs and consequences of vendor heterogeneity 0 0 2 3 0 0 18 26
Regulatory Agency Discretion among Competing Industries: Inside the FDA 0 0 0 0 0 0 6 196
Regulatory Reform and Bureaucratic Responsiveness to Firms: the Impact of User Fees in the FDA 0 0 0 25 0 1 15 137
Substitution in Regulatory Agencies: FDA Enforcement Alternatives 0 0 0 0 1 1 5 205
The Effects of UK Pharmaceutical Policy on Government Drug Expenditure: Cost Control and Incentives for R&D 0 0 0 12 0 0 6 76
The risk we bear: The effects of review speed and industry user fees on new drug safety 0 0 2 28 1 2 10 147
Total Journal Articles 0 0 8 175 6 13 147 1,960


Statistics updated 2026-10-11